Clover Health Investments, Corp. CLOV
3.73 USD -0.04 (-1.06%)
Regular-session close
3.75 +0.02 +0.57%
After hours · Nov 20, 7:55 PM ET
3.68 Day range 3.96
1.58 52-week range 5.59
- YTD
- +58.72%
- 1 year
- +72.69%
5D -1.30 (-25.84%)
- Market cap
- 2.00B
- Revenue (ttm)
- 2.74B
- Profit margin
- 0.45%
- EPS (ttm)
- 0.01
- Shares out
- 439.71M
- P/E ratio
- 373.00
- Forward P/E
- 20.72
- YTD return
- +58.72%
- 1-year return
- +72.69%
- Volume
- 7.25M
- Avg volume
- 4.42M
- Open
- 3.77
- Previous close
- 3.77
- Day's range
- 3.68 – 3.96
- 52-week range
- 1.58 – 5.59
- Beta
- 2.48
- Price target
- 5.60 (+50.1%)
- Earnings date
- Feb 25, 2027
Key statistics
- 50-day average
- 4.61
- 200-day average
- 3.70
- Enterprise value
- 1.69B
- Price / sales
- 0.73
- Price / book
- 5.09
- Revenue growth
- 53.10%
- Free cash flow
- 87.48M
- Total cash
- 332.74M
- Return on equity
- 3.40%
- Short % of float
- 5.43%
Fundamental scorecard
13 of 25 checks passed on CLOV’s reported financials
13of 25 checks passed
- Value 1 of 5
- Growth 4 of 5
- Profitability 3 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
Price target (mean) 5.60 +50.1% upside
Now 3.73
- Target (low)
- 5.00
- Target (mean)
- 5.60
- Target (high)
- 6.00
Ratings (0m) 5 3 buy · 2 hold · 0 sell
- Strong buy1
- Buy2
- Hold2
- Sell0
- Strong sell0
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate -0.03.
Financials — quick view
CLOV Revenue — quarterly 759.30M
CLOV Net income — quarterly 6.43M
CLOV EPS — quarterly 0.01
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | -0.05 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -0.00507 | 0.01 | +0.02 | +297.24% |
| Aug 5, 2026 | Jun 30, 2026 | 0.03864 | 0.05 | +0.01 | +29.40% |
| May 6, 2026 | Mar 31, 2026 | 0.07 | 0.07 | 0.00 | 0.00% |
| Feb 26, 2026 | Dec 31, 2025 | -0.10212 | -0.05 | +0.05 | +51.04% |
| Nov 4, 2025 | Sep 30, 2025 | 0.02 | -0.05 | -0.07 | -350.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | UBS | main | Neutral | Neutral |
| Oct 28, 2026 | Needham | init | — | Buy |
| Aug 6, 2026 | UBS | main | Neutral | Neutral |
| Jul 21, 2026 | Canaccord Genuity | main | Buy | Buy |
| Jun 11, 2026 | UBS | main | Neutral | Neutral |
| Jun 4, 2026 | Canaccord Genuity | main | Buy | Buy |
About Clover Health Investments, Corp.
Clover Health Investments, Corp. provides medicare advantage plans in the United States. The company offers preferred provider organization and health maintenance organization plans to medicare-eligible individuals. It also operates Clover Assistant, a software platform for physicians to detect, identify, and manage chronic diseases. The company was founded in 2014 and is based in Wilmington, Delaware.
- Sector
- Healthcare
- Industry
- Healthcare Plans
- Country
- United States
- Website
- cloverhealth.com
News
UnitedHealth Stock Slips: What's Going On?
Medicare, Medicaid Overhaul Targets Fraudulent Billing and Unauthorized Marketplace Enrollments UBS Maintains Neutral on Clover Health Investments, Raises Price Target to $5.5
Clover Health Investments Raises FY2026 Sales Guidance from $2.920B-$3.000B to $2.970B-$3.000B vs $2.954B Est
Clover Health Investments Q3 EPS $0.01 Beats $(0.00) Estimate, Sales $759.304M Beat $738.423M Estimate
This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Needham Initiates Coverage On Clover Health Investments with Buy Rating, Announces Price Target of $6
Your note
Sign in to keep a note on CLOV — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CLINTON CHELSEA | Director | Stock Award(Grant) | Jan 5, 2025 | 602,814 |
| GARIPALLI VIVEK | Director and Beneficial Owner of more than 10% of a Class of Security | Conversion of Exercise of derivative security | Jan 6, 2026 | 1,856,250 |
| KOUZOUKAS DEMETRIOS L | Director | Stock Award(Grant) | Jan 5, 2026 | 605,980 |
| KUIPERS PETER J | Chief Financial Officer | Stock Award(Grant) | May 18, 2025 | 6,349,970 |
| PRIEST BRADY PATRICK | Officer | Sale | May 12, 2026 | 2,040,220 |
| REYNOSO JAMIE L. | Officer | Sale | Oct 18, 2026 | 2,770,350 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.30% | 36,508,668 | 136.18M | Sep 29, 2026 |
| Vanguard Capital Management LLC | 4.18% | 18,381,770 | 68.56M | Sep 29, 2026 |
| Geode Capital Management, LLC | 2.53% | 11,115,990 | 41.46M | Sep 29, 2026 |
| State Street Corporation | 2.43% | 10,693,705 | 39.89M | Sep 29, 2026 |
| Nuveen, LLC | 1.78% | 7,818,023 | 29.16M | Sep 29, 2026 |
| Vanguard Portfolio Management LLC | 1.73% | 7,590,927 | 28.31M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.95% | 12,979,049 | 48.41M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.48% | 10,923,260 | 40.74M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 1.06% | 4,646,552 | 17.33M | Jun 29, 2026 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 1.05% | 4,607,350 | 17.19M | Aug 30, 2026 |
| iShares Trust-iShares Russell 2000 Growth ETF | 0.89% | 3,928,211 | 14.65M | Sep 29, 2026 |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | 0.55% | 2,411,215 | 8.99M | Aug 30, 2026 |
